|Bid||88.91 x 100|
|Ask||91.36 x 100|
|Day's Range||89.27 - 91.80|
|52 Week Range||84.25 - 147.17|
|PE Ratio (TTM)||24.62|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.
Celgene Corporation (CELG) is an integrated global biopharmaceutical company focused on innovative therapies for treating cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation. Celgene’s Otezla is an oral small molecule inhibitor of PDE4. Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in the United States, Japan, the European Union, and other international markets.
On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion.
Celgene (CELG) is one of the leading biopharmaceutical companies, with headquarters in New Jersey. Celgene’s product portfolio includes drugs for the treatment of cancer and inflammatory diseases.
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
The US pharmaceutical sector is made up of different setups pertaining to the development, manufacturing or production, and marketing of drugs. These setups consist of drug manufacturers, drug marketers, and biotechnology companies.
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.
Holding any stock for multiple decades might sound crazy, but it's proven to be a path to huge profits. Here are three stocks worthy of (very) long-term ownership.
Gilead's viral franchises look strong heading into the first-quarter earnings season, but Biogen and Celgene are on shakier ground, an analyst says.
Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.
Among the companies with shares expected to trade actively in Tuesday's session are Spotify, Amazon, Apple, Tesla, General Motors and Intel.
Celgene Corp. shares added to Monday's losses in the extended session after the biotech said its president and chief operating officer, Scott Smith, was leaving the company immediately. Celgene shares ...
A top executive who helped launch Celgene's third biggest moneymaker unexpectedly departed the No. 3 biotech late Monday.